Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 6/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14199037 | 0.85 | ALDH1A1 (0.48) | CNR2ALDH1A1CREBBPSMN1; SMN2KMT2A | |
| SCHEMBL7778088 | 0.85 | CNR2 (0.70) | CNR2ALDH1A1HTR6CREBBPSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9354397 | 0.83 | CNR2 (0.68) | CNR2ALDH1A1HTR6CREBBPSMN1; SMN2 | |
| SCHEMBL2033409 | 0.82 | CNR2 (0.60) | CNR2ALDH1A1HTR6CREBBPCNR1 | |
| SCHEMBL9353785 | 0.81 | NR4A2 (0.68) | CNR2ALDH1A1SMN1; SMN2CNR1KMT2A | |
| SCHEMBL3242026 | 0.80 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL2077848 | 0.79 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL13013345 | 0.77 | CNR2 (0.54) | CNR2ALDH1A1SMN1; SMN2CNR1KMT2A | |
| SCHEMBL6867354 | 0.75 | CNR2 (0.58) | CNR2HTR6SMN1; SMN2CNR1KMT2A | |
| Hydrochloric Acid SCHEMBL8692389 | 0.75 | CNR2 (0.58) | CNR2ALDH1A1HTR6CREBBPCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-08-11 | — | — | US | disclosed |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | TPH2, AANAT, HTR2C | CNR2 17/4885ALDH1A1 1164/4885HTR6 10/4885 |
| US-20220251040-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | CNR2 17/4885ALDH1A1 1164/4885HTR6 10/4885 |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | CNR2 17/4885ALDH1A1 1164/4885HTR6 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.